Navigation Links
Ivivi's PEMF Technology Significantly Improves Neuron Survival in,Parkinson's Disease Model, Study Finds

NORTHVALE, N.J.--(BUSINESS WIRE)--Jun 12, 2007 - Proprietary Pulsed Electromagnetic Field (PEMF) technology, developed by Ivivi Technologies, Inc. (AMEX:II), improved neuron survival in a standard animal cell model of brain inflammation, researchers reported today in a platform presentation at the Bioelectromagnetics Society (BEMS, http://www.bioelectromagnetics.org) Annual Meeting, in Kanazawa, Japan. Inflammation is associated with neuron death that occurs in Parkinson's disease and other neurodegenerative conditions in humans. The preliminary data, from studies conducted by Dr. Diana Casper, neurobiologist at Albert Einstein College of Medicine (NY), indicates that certain PEMF therapies could be neuroprotective.

"Dopaminergic neurons, which die in Parkinson's disease, are clearly susceptible to inflammation," said Dr. Diana Casper. "If we could keep sufficient numbers of them alive, we possibly could keep patients from exhibiting the symptoms associated with Parkinson's. In this model, PEMF signals appeared to both reduce levels of inflammation as well as protect neurons from inflammatory effects."

"Dr. Casper's work demonstrated that our PEMF signals doubled neuron survival in cultures that were subjected to inflammation-creating chemical insult," commented Sean Hagberg, Ph.D., Chief Science Officer, Ivivi Technologies. "While the primary pathological events in neurodegenerative conditions such as Parkinson's disease are still unknown, the potential to delay or prevent the death of dopaminergic neurons could provide new opportunities for Ivivi."

Andre' DiMino, Co-CEO, Ivivi Technologies noted, "This neurological study confirms our commitment to develop innovative, non-invasive and non-pharmacologic electrotherapies, targeting fundamental disease processes common to many of the most debilitating and challenging illnesses. Our mission is to expand applications of our proprietary electrotherapeu tic technologies as we intend to continue to develop our technology for this and other areas."

About Ivivi Technologies, Inc.

Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi's research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company's Electroceuticals(TM) have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders.

Forward-Looking Statements

This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the statements related to the preliminary data discussed above. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company's limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company's products to continue to develop, the inability for c ustomers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company's intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company's products and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's registration statement on Form SB-2. The Company assumes no obligation to update the information contained in this press release.

Contact

Investor Relations:
Cameron Associates
Alison Ziegler or Lester Rosenkrantz, 212-554-5469
Alison@cameronassoc.com
or
Media:
Deanne Eagle, 212-554-5463
Deanne@cameronassoc.com
or
Public Relations:
Avalanche Strategic Communications
Denyse Dabrowski, 201-488-0049
Mobile: 201-916-7122
Denyse@avalanchepr.com


'"/>




Related medicine technology :

1. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
2. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
6. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... May 15, 2017  Amy Baxter MD, chief executive ... in noninvasive pain relief, was awarded a 2017 Top ... Baxter was recognized at the MM&M Top 40 Healthcare ... City on May 10, 2017. The dinner ... industry go "beyond the pill."  "Innovation goes ...
(Date:5/11/2017)... -- Thornhill Research Inc. ( Toronto, Ontario, Canada ... five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the U.S. Department ... ( Ottawa, Ontario, Canada ) to ... to patients requiring emergency medical procedures in a ... have been a longtime partner with Thornhill Research ...
(Date:5/10/2017)... -- The Corporate Whistleblower Center says, "We are urging ... to call us anytime at 866-714-6466 if they possess ... a substantial scheme to overbill Medicare. We are ... of a medical equipment company if their employer ... practice groups with extra generous incentives to use, or ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey and ... creation of published authors, Bob and Margaret Massey. Bob Massey is small in stature ... and leather tough." His love for others is apparent in all of his life ...
(Date:5/26/2017)... ... ... the Garden of Eden”: retells the stories of three Bible figures in modern terms. ... Colt, mother, trader, horse farmer, artist and a former GM journeyman. Born in 1953 ... they moved to Dayton, Ohio, where Penny graduated high school. At sixteen, she toured ...
(Date:5/26/2017)... ... 2017 , ... Water damage to the flooring of several classrooms at The ... officials with a number of critical issues to address before students could return to ... with little or no disruption to class schedules. Second, the project had to comply ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... background. Understanind and choosing the most appropriate instruments for research and understanding the ... research finding. This webinar will focus on innovations in stereo microscopy for brightfield ...
(Date:5/24/2017)... ... May 24, 2017 , ... Altec Products, Inc., a ... 2017 – a one-day technology conference in San Diego, CA. , At nVerge ... users to fully utilize and enhance their Sage ERP solutions by providing improved visibility ...
Breaking Medicine News(10 mins):